Voyager Q2 net loss narrows to $24.5M; cash $148.8M, runway into 2028; tau programs on track for Q4 data

Voyager Therapeutics, Inc.

2026-Q2 EPS reported -$0.87 revenue$5,758,000

Net loss $24.5M in Q2 2026 vs $33.4M in Q2 2025; collaboration revenue $3.2M (down from $5.2M).
Cash, equivalents, and marketable securities $148.8M as of June 30, 2026; expected to fund operations into 2028.
VY7523 tau PET imaging data expected Q4 2026; VY1706 tau gene therapy IND cleared, dosing expected Q4 2026.
Neurocrine partner intends to initiate NBIB-223 trial for Friedreich's ataxia in H2 2026 pending FDA IND clearance.
R&D expenses $22.0M (down from $31.3M) and G&A $7.5M (down from $10.5M) due to prioritization and restructuring.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.